[1］Durdux C. Cisplatin and derivatives with radiation therapy： for what clinical use?[J］.Cancer Radiother，2004，8(Suppl 1)：88. [2］Muggia FM， Fojo T. Platinums： extending their therapeutic spectrum[J］.J Chemother，2004，16（Suppl 4）：77. [3］赵燕，汪森明，张健.泰素联合顺铂动、静脉给药治疗晚期非小细胞肺ca的疗效比较[J］.癌症，2002，21(12)：1365. [4］Belani CP， Eckardt J. Development of docetaxel in advanced non-small-cell lung cancer[J］.Lung Cancer，2004，46(Suppl 2)：3. [5］Muggia FM. Relevance of chemotherapy dose and schedule to outcomes in ovarian cancer[J］.Semin Oncol，2004，31(6 Suppl 15)：19. [6］Li HC， Russell CA. Gemcitabine and platinum-based chemotherapy in metastatic breast cancer[J］.Oncology (Huntingt)，2004，18(14 Suppl 12)：17. [7］Camargo SM， Francescato HD， Lavrador MA，et　al.Oral administration of sodium selenite minimizes cisplatin toxicity on proximal tubules of rats[J］.Biol Trace Elem Res，2001，83：251. [8］Leonetti C，Biroccio A，Gabellini C，et　al.Alpha-tocopherol protects against cisplatin-induced toxicity without interfering with antitumor efficacy[J］.Int J Cancer，2003，104(2)：243. [9］amamoto R，Kaneuchi M，Nishiya M，et　al.Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer[J］.Cancer Chemother Pharmacol，2002，50(2)：137. [10］Ognoni A，Pensa F，Vaira F，et　al.A dose finding study of carboplatin and gemcitabine in advanced non-small cell lung cancer[J］.J Chemother，2002，14(3)：296. [11］湛永滋，黄昌杰，黄剑锋，等. 吉西他滨联合卡铂治疗晚期非小细胞肺癌[J］.中国肺癌杂志，2004，7(2)：168. [12］Kouroussis C ，Souglakos J ， Mavroudis D，et al. Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreaeol patients with advanced colorectal cancercacc[J］.AM J Clin Oncol，2002，25(6)：627. [13］Kohne CH. Palliative therapy of colorectal cancer[J］.Onkologie，2003，26(Suppl 7)：41. [14］van Cutsem E， Verslype C， Tejpar S. Oral capecitabine： bridging the Atlantic divide in colon cancer treatment[J］.Semin Oncol，2005，32(1)：43. [15］Louvet C， Andre T ， Tigaud JM，et al. phase Ⅱ study of oxaliplatin，fluorouracil ，and folinic acid in locally advanced or metastatic gastric cancer patients[J］.J　Clin　Oncol，2002，20(23)：4543. [16］Inaba H， Tsuda T， Miyazaki A，et al. Clinical study of the combination of small amount of nedaplatin(CDGP)/5-FU with radiation for the esophageal cancer[J］.Ninppon Shokakibyo Gakkai Zasshi，2002，99(10)：1191. [17］Vchida N，Yamada H， Maekewa R， et al. Combination chemotherapy of paclitaxel followed by nedaplatin for human ovarian cancer[J］.Gan Tokagaku Ryoho，2002，29(11)：1943. [18］Mckeage MJ. Lobaplatin：a new antitumor platinum drug[J］.Expert Opin Invecstig Drugs，2001，10(1)：119. [19］Jones S， Hainsworth J， Burris HA，et　al.Phase I study of JM-216 (an oral platinum analogue) in combination with paclitaxel in patients with advanced malignancies[J］.Invest New Drugs，2002，20：55. [20］Amorino GP， Mohr PJ， Hercules SK，et al. Combined effects of the orally active cisplatin analog， JM216， and radiation in antitumor therapy[J］.Cancer Chemother Pharmacol，2000，46：423. [21］Fokkema E， de Vries EG， Meijer S，et al.Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patients[J］.Cancer Chemother Pharmacol，2000，45：89. [22］Sternberg CN， Whelan P， Hetherington J，et　al.Phase Ⅲ trial of satraplatin， an oral platinum plus prednisone vs prednisone alone in patients with hormone-refractory prostate cancer[J］.Oncology，2005，68(1)：2. [23］Bagrova SG. Results of phase Ⅱ clinical trial of cycloplatam in refractory solid tumors[J］.Vopr Onkol， 2001， 47(6)：752. [24］Nersesyan A， Perrone E， Roggieri P，et　al. Genotoxic action of cycloplatam， a new platinum antitumor drug， on mammalian cells in vivo and in vitro[J］.Chemotherapy，2003，49(3)：132. [25］Verschraegen CF， Kumagai S， Davidson R， et al. Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans-R，R-1， 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles[J］.J Cancer Res Clin Oncol，2003，129(10)：549.